26 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Novozymes, bioinnovation and industrial enzymes, has reported five percent growth in first quarter of 2013.
"Overall, the first quarter was as expected. We're off to a satisfactory start in 2013, and we maintain the full-year outlook," said Mr Peder Holk Nielsen, who took office as Novozymes' CEO on April 1, 2013.
He also said, "Organic sales growth came in at the lower end of our full-year guidance, and we remain confident that it will pick up during the course of the year. We've executed well, and we're pleased that we can deliver an EBIT margin at this high level in the first quarter despite a little headwind from currency and acquisition costs."
"These are exciting times for Novozymes as we steer Novozymes forward in our quest to change the world together with our customers," he added.